Telix ADRs Fall After Company Discloses SEC Subpoena

Dow Jones

2025/07/24

By Dean Seal

Telix Pharmaceuticals' American depositary receipts dropped after the company disclosed that it has received a subpoena from the Securities and Exchange Commission.

The ADRs were down 10% at $1.60 in afternoon trading. They are now down 5% year to date.

The Melbourne, Australia-based company said in its second-quarter earnings report that the U.S. securities regulator is seeking various documents and information related to disclosures about the development of Telix's prostate-cancer therapeutic candidates.

Telix said it is fully cooperating with the SEC and in the process of responding to its request.

"At this stage, this matter is a fact-finding request," the company said.

The company has elected to notify the Australian Securities and Investments Commission about the SEC's inquiry. While the matter is ongoing, Telix plans to continue with its clinical-development programs related to its prostate-cancer therapy candidates.

Write to Dean at dean.seal@wsj.com

(END) Dow Jones Newswires

July 23, 2025 12:55 ET (16:55 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2553244422"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2553244422\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2553244422?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-24 00:55","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2553244422","market":"fut","top_or_hot":-1,"title":"Telix ADRs Fall After Company Discloses SEC Subpoena","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Dean Seal \n</p>\n<pre>\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/TLX.AU\">Telix Pharmaceuticals</a>' <a href=\"https://laohu8.com/S/AFG\">American</a> depositary receipts dropped after the company disclosed that it has received a subpoena from the Securities and Exchange Commission. \n</p>\n<p>\n  The ADRs were down 10% at $1.60 in afternoon trading. They are now down 5% year to date. \n</p>\n<p>\n  The Melbourne, Australia-based company said in its second-quarter earnings report that the U.S. securities regulator is seeking various documents and information related to disclosures about the development of Telix's prostate-cancer therapeutic candidates. \n</p>\n<p>\n  Telix said it is fully cooperating with the SEC and in the process of responding to its request. \n</p>\n<p>\n  \"At this stage, this matter is a fact-finding request,\" the company said. \n</p>\n<p>\n  The company has elected to notify the Australian Securities and Investments Commission about the SEC's inquiry. While the matter is ongoing, Telix plans to continue with its clinical-development programs related to its prostate-cancer therapy candidates. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Dean at dean.seal@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 23, 2025 12:55 ET (16:55 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Telix ADRs Fall After Company Discloses SEC Subpoena</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTelix ADRs Fall After Company Discloses SEC Subpoena\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-07-24 00:55</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Dean Seal \n</p>\n<pre>\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/TLX.AU\">Telix Pharmaceuticals</a>' <a href=\"https://laohu8.com/S/AFG\">American</a> depositary receipts dropped after the company disclosed that it has received a subpoena from the Securities and Exchange Commission. \n</p>\n<p>\n  The ADRs were down 10% at $1.60 in afternoon trading. They are now down 5% year to date. \n</p>\n<p>\n  The Melbourne, Australia-based company said in its second-quarter earnings report that the U.S. securities regulator is seeking various documents and information related to disclosures about the development of Telix's prostate-cancer therapeutic candidates. \n</p>\n<p>\n  Telix said it is fully cooperating with the SEC and in the process of responding to its request. \n</p>\n<p>\n  \"At this stage, this matter is a fact-finding request,\" the company said. \n</p>\n<p>\n  The company has elected to notify the Australian Securities and Investments Commission about the SEC's inquiry. While the matter is ongoing, Telix plans to continue with its clinical-development programs related to its prostate-cancer therapy candidates. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Dean at dean.seal@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 23, 2025 12:55 ET (16:55 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7067","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2553244422","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2553244422","pubTimestamp":1753289700,"columns":[{"name":"政策监管","id":32,"label_key":"policyRegulatory"}],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Telix Pharmaceuticals' American depositary receipts dropped after the company disclosed that it has received a subpoena from the Securities and Exchange Commission.The ADRs were down 10% at $1.60 in afternoon trading. They are now down 5% year to date.The Melbourne, Australia-based company said in its second-quarter earnings report that the U.S. securities regulator is seeking various documents and information related to disclosures about the development of Telix's prostate-cancer therapeutic candidates.Telix said it is fully cooperating with the SEC and in the process of responding to its request.\"At this stage, this matter is a fact-finding request,\" the company said.The company has elected to notify the Australian Securities and Investments Commission about the SEC's inquiry. While the matter is ongoing, Telix plans to continue with its clinical-development programs related to its prostate-cancer therapy candidates.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7067":"生物科技","TLX.AU":"TELIX PHARMACEUTICALS LTD"},"translate_title":"Telix ADR在公司披露SEC传票后下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TLX.AU":0.9},"content_text":"By Dean Seal \n\n\n \n\n\nTelix Pharmaceuticals' American depositary receipts dropped after the company disclosed that it has received a subpoena from the Securities and Exchange Commission. \n\n\n  The ADRs were down 10% at $1.60 in afternoon trading. They are now down 5% year to date. \n\n\n  The Melbourne, Australia-based company said in its second-quarter earnings report that the U.S. securities regulator is seeking various documents and information related to disclosures about the development of Telix's prostate-cancer therapeutic candidates. \n\n\n  Telix said it is fully cooperating with the SEC and in the process of responding to its request. \n\n\n  \"At this stage, this matter is a fact-finding request,\" the company said. \n\n\n  The company has elected to notify the Australian Securities and Investments Commission about the SEC's inquiry. While the matter is ongoing, Telix plans to continue with its clinical-development programs related to its prostate-cancer therapy candidates. \n\n\n \n\n\n  Write to Dean at dean.seal@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  July 23, 2025 12:55 ET (16:55 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}